Keyword: Regeneron Pharmaceuticals
Esperion plans to sell its non-statin cholesterol-fighting drugs at a price that ensures patients prescribed them can actually afford them.
Kodiak Sciences sold a capped 4.5% royalty on its eye disease drug that could rival Eylea in exchange for $225 million in development funding.
The takeover represents a big bet that a near-approval cholesterol drug will perform better commercially than rival anti-PCSK9 antibodies.
Most top R&D executives from across biopharma are earning around $7 million a year.
1. George Yancopoulos, Regeneron
The top research and development executives from across biopharma are certainly not looking down the back of the sofa for change; most are earning around $7 million a year. But then the job is tough, and arguably just as important as the top CEO job, given how much companies rely on the strength of their R&D.
The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.
The cash will push a treatment for non-Hodgkin lymphoma into the clinic and support the development of Adicet’s gamma delta T-cell platform.
Pfizer’s JAK inhibitor cleared patients’ skin and improved atopic dermatitis symptoms in a second phase 3 study.
Opthea tested its drug in combination with Lucentis, finding that the combo bested Lucentis alone at improving vision and reducing scarring in the retina.